CO2022004947A2 - Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente - Google Patents

Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente

Info

Publication number
CO2022004947A2
CO2022004947A2 CONC2022/0004947A CO2022004947A CO2022004947A2 CO 2022004947 A2 CO2022004947 A2 CO 2022004947A2 CO 2022004947 A CO2022004947 A CO 2022004947A CO 2022004947 A2 CO2022004947 A2 CO 2022004947A2
Authority
CO
Colombia
Prior art keywords
treatment
cell carcinoma
squamous cell
patients
locally advanced
Prior art date
Application number
CONC2022/0004947A
Other languages
English (en)
Inventor
Silvano Brienza
Claudio Zanna
Altman Sergio Adrian Szyldergemajn
Jean Bourhis
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of CO2022004947A2 publication Critical patent/CO2022004947A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

Se proporcionan métodos de administración de inhibidores de la proteína de la apoptosis ("IAP"), o sales farmacéuticamente aceptables de los mismos, para el tratamiento de un paciente humano que tenga un carcinoma de células escamosas localmente avanzado
CONC2022/0004947A 2019-09-25 2022-04-20 Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente CO2022004947A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962905703P 2019-09-25 2019-09-25
US202063016762P 2020-04-28 2020-04-28
EP20184601 2020-07-07
PCT/EP2020/076994 WO2021058794A1 (en) 2019-09-25 2020-09-25 Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma

Publications (1)

Publication Number Publication Date
CO2022004947A2 true CO2022004947A2 (es) 2022-08-30

Family

ID=72644266

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0004947A CO2022004947A2 (es) 2019-09-25 2022-04-20 Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente

Country Status (11)

Country Link
EP (1) EP4034102A1 (es)
JP (1) JP2022550037A (es)
KR (1) KR20220088700A (es)
CN (1) CN114727984A (es)
AU (1) AU2020356356A1 (es)
BR (1) BR112022005624A2 (es)
CA (1) CA3151770A1 (es)
CO (1) CO2022004947A2 (es)
IL (1) IL291682A (es)
MX (1) MX2022003628A (es)
WO (1) WO2021058794A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024022275A1 (zh) * 2022-07-29 2024-02-01 苏州科睿思制药有限公司 Xevinapant的晶型及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019671B1 (en) 2006-05-05 2014-09-24 The Regents Of The University Of Michigan Intermediates for the preparation of bivalent smac mimetics
EP2024362A4 (en) 2006-05-16 2012-01-25 Pharmascience Inc IAP BIR DOMAIN BINDING COMPOUNDS
US20100113326A1 (en) 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110218A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
BRPI0810522B8 (pt) 2007-04-13 2021-05-25 Univ Michigan Regents compostos miméticos diazo bicíclicos de smac, composição farmacêutica e kit compreendendo ditos compostos e uso dos mesmos para o tratamento de câncer
EP2296650B1 (en) 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
EP2491041B1 (en) 2009-10-23 2017-08-09 The Regents of the University of Michigan Bivalent diazo bicyclic smac mimetics and the uses thereof
WO2011059763A2 (en) 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
BR112012010698A2 (pt) 2009-11-05 2016-11-29 Uab Research Foundation método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ））
US8859541B2 (en) 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
AU2013306087B2 (en) 2012-08-23 2017-08-10 The Regents Of The University Of Michigan Bivalent inhibitors of IAP proteins and therapeutic methods using the same
CA2896577C (en) 2012-11-30 2024-01-23 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
WO2014121178A1 (en) 2013-02-04 2014-08-07 Tetralogic Pharmaceuticals Corp. Smac mimetic method of treatment
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
HUE056297T2 (hu) 2013-12-20 2022-02-28 Astex Therapeutics Ltd Biciklikus heterociklusos vegyületek és ezek terápiában történõ alkalmazása
AR101479A1 (es) 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
AU2015360095B2 (en) * 2014-12-09 2020-02-27 Advenchen Laboratories Nanjing Ltd Quinoline derivative against non-small cell lung cancer
CA2916970A1 (en) 2016-01-08 2017-07-08 Pharmascience Inc. A smac mimetic compound for use in the treatment of proliferative diseases
WO2017143449A1 (en) 2016-02-24 2017-08-31 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CN110475567A (zh) 2017-03-31 2019-11-19 勃林格殷格翰国际有限公司 抗癌组合疗法

Also Published As

Publication number Publication date
EP4034102A1 (en) 2022-08-03
IL291682A (en) 2022-05-01
AU2020356356A1 (en) 2022-05-12
CA3151770A1 (en) 2021-04-01
BR112022005624A2 (pt) 2022-07-12
MX2022003628A (es) 2022-07-21
KR20220088700A (ko) 2022-06-28
WO2021058794A1 (en) 2021-04-01
JP2022550037A (ja) 2022-11-30
CN114727984A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
CO2018006358A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR119158A1 (es) Tratamientos de angioedema hereditario
BR112017000556A2 (pt) terapia de combinação para câncer
AR119159A1 (es) Tratamientos de angioedema
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
CO2022004947A2 (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente
AR103118A1 (es) Tratamientos médicos basados en anamorelina
CL2021000444A1 (es) Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto.
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
EA202193276A1 (ru) Способы лечения холангиокарциномы